Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Clear all

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, ADT, Bicalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Localized Prostate Cancer, BPH (Benign Prostatic Hyperplasia), Prostate Cancer; Benign Prostatic Hyperplasia
Interventions: High Intensity Focused Ultrasound; Device
Lead sponsor: Sonablate; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 245
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more

Conditions: Prostate Cancer
Interventions: Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT); Drug · Other
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia

Conditions: Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
Interventions: Epidiolex Oral Liquid Product; Drug
Lead sponsor: Zin W Myint; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Prostate Cancer
Interventions: Extended Hypofractionation Radiotherapy, Accelerated Hypofractionation Radiotherapy; Radiation
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lymphoma
Interventions: cyclosporine; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 23
States / cities: Stanford, California • Aurora, Illinois • Berwyn, Illinois + 12 more

Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide; Drug · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 311
States / cities: Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, ADT, Relugolix; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 32
States / cities: Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Interventions: CyberKnife SBRT; Radiation
Lead sponsor: Crozer-Keystone Health System; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hodgkin Lymphoma
Interventions: Stanford V Chemotherapy, Radiation Therapy; Drug · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 6
States / cities: Palo Alto, California • San Diego, California • Peoria, Illinois + 3 more

Conditions: Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions: Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET); Procedure · Drug
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Prostate Cancer
Interventions: PSMA-guided Salvage Radiation; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 30 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions: 5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions: romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Biliary Cirrhosis
Interventions: Elafibranor 80mg, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 46
States / cities: Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Prostate Cancer
Interventions: Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI); Drug · Device
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions: dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method; Drug · Other · Genetic
Lead sponsor: Translational Oncology Research International; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 17
States / cities: Alhambra, California • Fullerton, California • Long Beach, California + 12 more

Conditions: Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus, Therapeutic Conventional Surgery; Biological · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Charlottesville, Virginia

Conditions: Prostate Cancer
Interventions: Neurovascular sparing stereotactic body radiation therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Malignant Prostate Neoplasm
Interventions: Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Radiation · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Biochemical Recurrence of Malignant Neoplasm of Prostate
Interventions: 64Cu-SAR-bisPSMA; Drug
Lead sponsor: Clarity Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Omaha, Nebraska • Albuquerque, New Mexico + 2 more

Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography; Procedure · Radiation · Other + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Sonablate HIFU International Registry for PC & BPH Patients

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

CyberKnife Dose Escalation Prostate Cancer Trial

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer